Agilent Technologies Diagnostics and Genomics — Depreciation remained flat by 0.0% to $14.00M in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 40.0%, from $10.00M to $14.00M. Over 3 years (FY 2021 to FY 2024), Diagnostics and Genomics — Depreciation shows an upward trend with a 12.8% CAGR.
An increase suggests a larger capital asset base or accelerated aging of existing manufacturing and research equipment.
This represents the systematic allocation of the cost of tangible assets, such as manufacturing equipment and laboratory...
Standard accounting expense for any capital-intensive manufacturing or research-based business.
a_segment_diagnostics_and_genomics_depreciation| FY'21 | FY'22 | FY'23 | FY'24 | |
|---|---|---|---|---|
| Value | $39.00M | $39.00M | $40.00M | $56.00M |
| YoY Change | — | +0.0% | +2.6% | +40.0% |